Close Menu

North America

The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.

In the dose expansion portion of the trial, CFI-402257 will be evaluated in three arms, including estrogen receptor-positive, HER2-negative breast cancer, TNBC, and solid tumor patients.

The agency approved the test for use across solid tumors and with multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.

The Phase II IRENE study will evaluate a virus-based treatment with an anti-PD1 checkpoint inhibitor in patients with triple-negative breast cancer.

Kinnate aims to advance its lead candidates into clinical trials next year and collaborate with investigators at precision cancer centers on future research projects.

The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.

Maple Grove, Minnesota-based Stemonix will merge in an all-equity transaction with a newly formed subsidiary of Cancer Genetics, which expects to remain listed on the Nasdaq.

Awaiting data from the Phase II SOLAR trial, miRagen is looking to potentially advance cobomarsen into registration-enabling studies for miR-155 elevated CTCL and ATLL.

The health system's Indianapolis-based Franciscan Health Cancer Center will adopt Deep Lens VIPER to match patients to trials based on the genetic profiles of their cancers.

A Sanford Cancer Center team is genomically profiling head and neck squamous cell cancer samples to look for biomarkers of immunotherapy and chemoradiation response.